Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Primary objective:
The primary objective is to demonstrate the superiority of Monoprost® versus Lumigan® 0.01%
and Lumigan® 0.03% Unit Dose in term of safety with respect to the assessment of conjunctival
hyperaemia in the worse eye at Day 84.
The conjunctival hyperaemia will be scored using the MacMonnies photographic scale (0 to 5).